Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Trump administration plan to reduce access to some student loans angers nurses, health care groups - 2The Force of Mentorship: Self-improvement through Direction
- 3Instructions to Pick the Right Toothpaste for Your Dental Requirements
- 4Vote In favor of Your Number one Game Control center
- 5Carry Nature Inside with These Staggering Plant Decisions
- Shah Capital pushes for Novavax sale, warns of proxy fight
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
- NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
- IDF destroys two-kilometer-long Gaza terror tunnel in Beit Lahiya
- The Main 20 Photography Instagram Records to Follow
- Find the Marvels of the World with These Travels
- Easy to understand Tech: Cell phones for Old in 2024
- Qatar, Ireland accuse Israel of using chemical weapons on Palestinians, demand watchdog probe use
